Clinical Trials Logo

Clinical Trial Summary

This study will include 5 cohorts of 14 flavivirus-naïve female subjects, 18 - 40 years of age (total: up to 70 subjects). Within each cohort, 10 subjects will receive ZIKV and 4 subjects will receive a placebo on Study Day 0. Cohorts 1 and 2 (Dose = 10^2 PFU) will be enrolled first. Cohorts 3 and 4 may be enrolled if dose escalation criteria are met (Section 3.1.2.3). Enrollment into Cohort 5 may occur if dose escalation criteria are met following enrollment into Cohorts 3 and 4. Only one ZIKV strain will be evaluated in Cohort 5.


Clinical Trial Description

This study is a placebo-controlled, double-blind study in normal healthy adult female subjects 18 - 40 years of age, inclusive, recruited from the metropolitan Baltimore/Washington, DC and Burlington, VT areas. The purpose of this study is to evaluate the clinical and virologic response to escalating doses of 2 different ZIKV strains administered subcutaneously in healthy, flavivirus-naïve, non-pregnant, female adult volunteers to identify the most suitable ZIKV strain and dose for use in a ZIKV CHIM. The ZIKV CHIM will then be used to evaluate the protective efficacy of candidate ZIKV vaccines prior to evaluation of these candidates in Phase 2 clinical trials. Both ZIKV strains will be studied at doses of 10^2 PFU and 10^3 PFU. Only one of the ZIKV strains will be studied at a dose of 10^4 PFU. The ZIKV strain to be studied at 10^4 PFU will be determined following review of the data from the 10^2 and 10^3 PFU cohorts. Placebo recipients are included in the study as a control to better assess ZIKV-associated versus non-ZIKV-associated AEs. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05123222
Study type Interventional
Source National Institute of Allergy and Infectious Diseases (NIAID)
Contact Madeleine Blunt
Phone (443) 610-8568
Email [email protected]
Status Recruiting
Phase Phase 1
Start date November 30, 2021
Completion date August 31, 2023

See also
  Status Clinical Trial Phase
Enrolling by invitation NCT04182685 - Evaluation of Medical Conditions Associated With Zika Virus Infection in Managua, Nicaragua
Enrolling by invitation NCT04398901 - Neurodevelopmental Outcomes in ZIKV-Exposed Children
Completed NCT02996890 - Zika-Vaccine Dose Finding Study Regarding Safety, Immunogenicity and Tolerability (V186-001) Phase 1
Active, not recruiting NCT03188731 - ZIKAlliance Pregnant Women Cohort
Completed NCT03110770 - VRC 705: A Zika Virus DNA Vaccine in Healthy Adults and Adolescents Phase 2
Recruiting NCT04917861 - A Study of Zika Vaccine mRNA-1893 in Adult Participants Living in Endemic and Non-Endemic Flavivirus Areas Phase 2
Completed NCT02794181 - Zika Virus and Related Arbovirus Infections in Deferred Blood Donors (ZVADD)
Recruiting NCT01099852 - Cohort of Patients Infected by an Arbovirus
Recruiting NCT03611946 - Evaluation of the Safety and Immunogenicity of the Live Attenuated Zika Vaccine rZIKV/D4Δ30-713 in Flavivirus-naïve Adults Phase 1
Completed NCT04064905 - Safety, Tolerability, and Immunogenicity of Zika Vaccine mRNA-1893 in Healthy Flavivirus Seropositive and Seronegative Adults Phase 1
Completed NCT03106714 - Study on the Persistence of Zika Virus (ZIKV) in Body Fluids of Patients With ZIKV Infection in Brazil
Completed NCT02979938 - Understanding Excretion and Infectivity of Zika Virus in Semen During and After Infection
Recruiting NCT03227601 - Effect of a Posture Adapter for 12 to 24-month Children With Zyka Virus Syndrome N/A
Recruiting NCT03393286 - ZIKAlliance Children Cohort (ZIKAllianceCH)
Completed NCT03425149 - Randomized, Placebo-controlled, Observer-blinded Phase 1 Safety and Immunogenicity Study of Inactivated Zika Virus Vaccine Candidate in Healthy Adults Phase 1
Completed NCT02733796 - Persistence of Zika Virus in Semen After Acute Infection
Completed NCT03014089 - Safety, Tolerability, and Immunogenicity of mRNA-1325 in Healthy Adult Subjects Phase 1
Completed NCT03263195 - Prospective Cohort Study of HIV and Zika in Infants and Pregnancy
Suspended NCT03204409 - ZIKAlliance Natural History Study